Evaluation of Levodopa for Parkinsonism. Levodopa (Dopar, Larodopa).
D000208:Acute Disease; D000284:Administration, Oral; D000367:Age Factors; D001812:Blood-Brain Barrier / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004357:Drug Synergism; D004361:Drug Tolerance; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D013788:Thalamus / Q000601:surgery; D013997:Time Factors
D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine